STE90-C11 antibody derived from human IgG1 with FcγR-silenced Fc can tolerate most known emerging RBD mutations, and inhibit SARS-CoV-2 binding to ACE2 (Bertoglio et al., 2021), which could treat severe COVID-19. This evidence concerns the gene ACE2 and COVID-19.